title: [An experience of using divasa in the treatment of cerebrovascular insufficiency].
abstract: OBJECTIVE
  To evaluate the clinical efficacy and safety of divasa in the treatment of patients with cerebrovascular insufficiency.
  
  
  METHODS
  The main group included 40 patients (mean age 56.2±5.7 years) with asthenic/autonomic and vestibular/ataxic disorders developed during chronic cerebrovascular disease. The severity of symptoms was measured with the Visual Analogue scale (VAS). Neuropsychological and psychoemotional status was assessed with MMSE, MFI-20, HAM-A, a subjective sleep questionnaire, a scheme for detection of signs of autonomic disorders. Quality of life questionnaire (SF-36) and CGI scale were used as well. The plasma levels of fibrinogen and the von Willebrand factor were determined in all patients. The control group included 40 patients with chronic cerebrovascular insufficiency matched for age, sex and severity of neurological symptoms to the main group.
  
  
  RESULTS
  The scores of asthenic symptoms, anxiety, sleep disorders and autonomic disorders were decreased significantly that led to the improvement of quality of life of patients. A significant decrease and normalization of the plasma levels of fibrinogen and the von Willebrand factor were identified in the patients of the main group. The drug was well-tolerated, side-effects (allergic reactions) were noted only in 5%.
  
  
  CONCLUSIONS
  The positive effect of divasa on patient's condition was demonstrated. The drug may be recommended for the use in complex treatment of these patients.
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: E I
authors.initials: EI
authors.lastname: Chukanova
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: A N
authors.initials: AN
authors.lastname: Bogolepova
authors.affiliation: Pirogov Russian National Research Medical University, Moscow.
authors.forename: A S
authors.initials: AS
authors.lastname: Chukanova
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy / Q000209:etiology; D001247:Asthenia / Q000188:drug therapy / Q000209:etiology; D002561:Cerebrovascular Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D052250:Nitric Oxide Synthase Type III / Q000276:immunology; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D009418:S100 Proteins / Q000276:immunology; D012893:Sleep Wake Disorders / Q000188:drug therapy / Q000209:etiology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D009418:S100 Proteins; D052250:Nitric Oxide Synthase Type III